Directorio

We are doing this study to find out if an investigational drug called HM43239 (the study drug) is a safe and effective option for people who have AML that came back after remission or did not respond to standard treatments. We also want to find out what dose of the study drug works best for most patients.

Before joining the main part of the study, you will have some tests to see if you qualify. These tests include check-ups for your body, skin, eyes, and nerves, as well as heart tests, an MRI scan, and bloodwork. If you qualify, you will have more tests every few cycles. A cycle is 28 days. These tests include check-ups, eye exams, blood tests, a stool sample, and MRI scans. After the treatment part of the study, you will be in a follow-up study called PNOC COMP. This part will look at how your thinking, daily life, and feelings change over time. You will get a different form to learn more about that part of the study.

In this study, you will be placed by chance into one of three groups. One group will get a medicine called daraxonrasib. Another group will get daraxonrasib plus two other medicines called gemcitabine and nab paclitaxel. The third group will get gemcitabine and nab paclitaxel without daraxonrasib. You will keep taking the study medicines as long as they are safe for you. The study is planned to last three years. Within thirty days after your last dose, you will have a follow up visit. After that, the study team will contact you every three months to check on your health until the study ends.

This study has two groups, and you will have an equal chance of being in either one. In Group 1, people get the usual treatment for advanced prostate cancer. This includes hormonal therapy, which can be given as a shot or as pills, and apalutamide, which is taken as four pills once a day. In Group 2, people get a chemotherapy drug called docetaxel along with the usual hormonal therapy and apalutamide. Docetaxel is given through a vein every three weeks for up to six doses. People in this group also get steroids through an IV on the day they receive docetaxel to help reduce side effects.

We are doing this study to compare two different treatment options for mantle cell lymphoma. We want to find out which option has the best outcomes for older adults. We will compare the results of continuous treatment with zanubritinib to treatment with zanubrutinib that is stopped after the initial six 28-day cycles of chemotherapy and restarted only if your disease gets worse following the initial six 28-day cycles of chemotherapy.

We are doing this study to help create a national biobank of samples and data about patients who experience side effects when they take immunotherapy drugs for their cancer. We want to find out why some people experience side effects and why others do not. We also want to learn more about how to diagnose and treat these side effects more effectively.

We are doing this study to test a new strategy to help people quit smoking. We want to know if the study approach is better than the usual approach. The usual approach is to encourage patients to quit smoking using cessation support manuals and either medication or nicotine replacement products. We want to know if the study approach works better for cancer survivors who live in rural areas.